BiotechTube

Votoplam (blinded) + Placebo

Phase 3Recruiting
0 views this week 0 watching⚡ Active
Interest: 47/100
47
Hype Score

Development Stage

✓
Pre-clinical
✓
Phase 1
✓
Phase 2
4
Phase 3
5
Approved
Indication / Disease

Huntington Disease

Conditions

Huntington Disease

Trial Timeline

Jun 1, 2026 → Apr 30, 2030

NCT ID
NCT07326709

About Votoplam (blinded) + Placebo

Votoplam (blinded) + Placebo is a phase 3 stage product being developed by Novartis for Huntington Disease. The current trial status is recruiting. This product is registered under clinical trial identifier NCT07326709. Target conditions include Huntington Disease.

What happened to similar drugs?

1 of 10 similar drugs in Huntington Disease were approved

Approved (1) Terminated (2) Active (7)
✅TetrabenazineLundbeckApproved
🔄RO7234292 (RG6042)RochePhase 3
🔄RO7234292 + PlaceboRochePhase 3
🔄DimebonPfizerPhase 3
❌Dimebon (latrepirdine)PfizerPhase 3
🔄RiluzoleSanofiPhase 3
🔄ValbenazineNeurocrine BiosciencesPhase 3

Hype Score Breakdown

Clinical
17
Activity
15
Company
15
Novelty
0
Community
0

Clinical Trials (1)

NCT IDPhaseStatus
NCT07326709Phase 3Recruiting

Competing Products

20 competing products in Huntington Disease

See all competitors
ProductCompanyStageHype Score
atomoxetine + Matching PlaceboEli LillyPhase 2
35
VotoplamNovartisPhase 2
39
Branaplam + PlaceboNovartisPhase 2
27
AFQ056 + PlaceboNovartisPhase 2
27
RO7234292 (RG6042)RochePhase 1
29
Tominersen + PlaceboRochePhase 2
39
RO7234292 (RG6042)RochePhase 3
40
RO7234292 (RG6042)RochePhase 2
35
RG6496 + PlaceboRochePhase 1
36
RO7234292 + PlaceboRochePhase 3
40
PF-02545920 + PF-02545920PfizerPhase 2
35
Dextromethorphan + Dimebon + DextromethorphanPfizerPhase 1
29
DimebonPfizerPhase 3
40
Dimebon (latrepirdine)PfizerPhase 3
32
20 mg BID of PF-02545920PfizerPhase 2
27
PF-02545920 + Placebo + PF-02545920 + PlaceboPfizerPhase 2
35
RiluzoleSanofiPhase 3
40
ALN-HTT02 + PlaceboAlnylam PharmaceuticalsPhase 1
33
TetrabenazineLundbeckApproved
36
ValbenazineNeurocrine BiosciencesPhase 3
41